What limits primary drying shelf temperature for epirubicin HCl lyophilisates below the collapse boundary?

Lyophilised epirubicin hydrochloride for injection requires a formulation and cycle design that keeps the product below the collapse temperature (Tc) of the cryoprotectant-API matrix, not merely below the freezing point. Epirubicin hydrochloride is supplied as a hygroscopic orange-red crystalline powder with pH-dependent aqueous solubility; when compounded for lyophilisation, the API is dissolved in water for injection at 2–8 °C, and the pH is adjusted with dilute hydrochloric acid to a target range of 3.0–4.5 to maintain the protonated form and limit glycosidic hydrolysis. The addition ratio is not fixed by the European Pharmacopoeia or USP monograph; development batches evaluate cryoprotectant-to-API mass ratios from 20:1 to 80:1 (mannitol or lactose) at a pre-lyophilisation API concentration of 1–5 mg/mL. The solution is sterilised through a 0.22 µm polyethersulfone sterilising-grade membrane with a pre-filter pressure differential below 2.0 bar, then aseptically filled into tubular glass vials and partially stoppered. Freeze-drying is performed in a production-scale lyophiliser with shelf temperature ramp to −40 °C at 0.5–1.0 °C/min, primary drying at shelf temperatures between −30 °C and −10 °C under chamber pressure of 0.1–0.3 mbar, and secondary drying at 20–30 °C for not more than 12 h. Compliance for this operation is anchored to EU GMP Annex 1, FDA 21 CFR 211, ICH Q3C, ICH Q3D, USP <71>, USP <85>, USP <788>, and the relevant Ph. Eur. epirubicin hydrochloride monograph. Finished product types are single-dose vials reconstituted to 2 mg/mL epirubicin base for intravenous bolus or further dilution in 0.9% sodium chloride or 5% glucose infusion bags. Operational boundaries: the lyophilised cake is hygroscopic; residual moisture above 2.0% w/w accelerates hydrolysis, and stopper capping under vacuum or nitrogen excludes moisture ingress. Avoid alkaline diluents after reconstitution because a pH shift above 6.0 induces precipitation and degradation.

The primary critical control point on a production lyophiliser is the collapse temperature of the frozen matrix; anthracycline formulations with mannitol can exhibit Tc values between −28 °C and −20 °C, but epirubicin-specific formulated products require freeze-drying microscopy and differential scanning calorimetry to assign the batch-specific Tc. When the shelf temperature is set too close to Tc, edge vials in a 20 m² shelf array can exceed the centre-vial temperature by a measurable ±2 °C because of radiation from the chamber walls and condenser ice loading above 80% of rated capacity. In this condition, the cake collapses at the bottom near the vial base, producing a shrunken mass, residual moisture above 2.0% w/w, and reconstitution times exceeding 3 min. The corrective action is to lower primary drying shelf temperature by 5 °C below the measured Tc, extend hold time rather than increase shelf temperature, and verify heater ramp uniformity across the shelf array with thermocouple mapping. Nitrogen backfill pressure during stoppering is maintained at 0.8–1.0 atm to prevent moisture ingress, and vial crimping torque is verified to avoid elastomer leakage. The batch release dossier therefore includes cake appearance, residual moisture by Karl Fischer titration, assay by HPLC at 254 nm, related substances, sterility, and endotoxin results linked to the approved product specification.

In ready-to-dilute concentrate manufacturing, terminal steam sterilisation is not a viable route for epirubicin HCl because the anthracycline glycosidic linkage is susceptible to hydrolytic degradation under autoclave temperatures above 121 °C; aseptic membrane filtration is therefore the only validated sterilisation route. The solution is compounded at 2 mg/mL epirubicin base in water for injection with sodium chloride 9 mg/mL as tonicity modifier, adjusted to pH 3.0–4.5 with hydrochloric acid, and cooled to 2–8 °C before transfer to the filling line. The addition ratio is fixed by the finished product specification: every millilitre contains 2 mg epirubicin base as the hydrochloride salt and 9 mg sodium chloride. The solution is passed through a 0.22 µm sterilising-grade membrane with a supplier-validated bubble point and a filtration pressure not exceeding 2.5 bar; pre- and post-filtration integrity testing is mandatory under EU GMP Annex 1. Aseptic filling occurs into Type I borosilicate glass vials in a Grade A/ISO Class 5 environment with Grade B/ISO Class 7 background; the vials are closed with fluoropolymer-coated elastomeric stoppers and aluminium seals. Release testing includes USP <71> sterility, USP <85> bacterial endotoxins, USP <788> subvisible particles, USP <790> visible particles, ICH Q3C residual solvents, and ICH Q3D elemental impurities, with potency confirmed by stability-indicating HPLC at 254 nm against the Ph. Eur. epirubicin hydrochloride monograph. Downstream, the concentrate is diluted to 0.2–1.0 mg/mL in 0.9% sodium chloride or 5% glucose; the diluted infusion should be protected from light and used within the beyond-use date assigned under USP <797> categories. Finished product types are single-dose vials of ready-to-dilute concentrate, not multiple-dose presentations. Operational limitations include incompatibility with alkaline buffers and with any diluent that raises pH above 6.0, which can precipitate the free base and accelerate hydrolysis. Freezing of the concentrate is not permitted; storage is at 2–8 °C in light-protected cartons, and excursions outside this range must be evaluated against ICH Q1A stability protocols.

Intravesical instillation compounding under closed-system transfer protocols

Compounding of intravesical epirubicin hydrochloride at 1 mg/mL requires a closed-system transfer device because the API is classified as a hazardous drug in the NIOSH antineoplastic list and the finished instillation presents occupational exposure risk during syringe transfer. The addition ratio for this route is standardised in institutional protocols at 50 mg epirubicin hydrochloride in 50 mL 0.9% sodium chloride injection, yielding 1 mg/mL; some protocols reduce the diluent volume to 40 mL or 30 mL for shorter bladder residence protocols, generating concentrations up to 1.7 mg/mL, but the 50 mL volume is the most common published practice. Preparation takes place in an ISO Class 5 biological safety cabinet within an ISO Class 7 cleanroom buffer zone, following USP <797> medium-risk sterile compounding categories and USP <800> hazardous drug containment. The lyophilised powder is reconstituted to 2 mg/mL before further dilution, or a ready-to-dilute concentrate is transferred; all connections are made with a 0.22 µm closed-system transfer device membrane or needle-free closed device to prevent leakage and aerosol formation. The finished product is a single-use bladder instillation syringe or a sterile connection to a urinary catheter set; the product is retained for 60 min and then drained. Beyond-use dating assigned under USP <797> for this admixture is typically not more than 12 h at 2–8 °C when sterility cannot be guaranteed beyond that window; the pH of the final admixture must remain in the range 3.0–6.0 to avoid precipitation. This process must not use terminal sterilisation, and the compounding record must include gravimetric verification of API volume, lot traceability, and closed-system transfer device integrity testing.

For oral tablet and capsule feasibility batches, epirubicin hydrochloride is treated as a high-potency low-dose API rather than a conventional direct-compression compound because oral bioavailability is restricted by acid-mediated degradation in the gastric compartment and P-glycoprotein efflux in the intestinal epithelium. No commercial oral monograph for epirubicin hydrochloride exists in USP or Ph. Eur., and published data for a fixed oral tablet/capsule formulation ratio are limited; feasibility work therefore begins with preformulation screening at 0.5–2.0 wt% API in a direct-compression blend of mannitol and microcrystalline cellulose. The addition ratio is constrained by content uniformity acceptance value AV ≤ 15 under USP <905> and by cleaning-validation limits for cytotoxic residues, not by tablet hardness or flow alone. Because epirubicin hydrochloride is hygroscopic and moisture-sensitive, wet granulation is avoided; dry granulation by slugging or roller compaction with a 1.0 mm screen is preferred for granule intermediates intended for capsule filling. Processing is conducted in a containment isolator with relative humidity ≤ 30% and temperature 18–25 °C, with high-efficiency particulate air filtration and surface wipe sampling for residual epirubicin. Analytical control includes stability-indicating HPLC at 254 nm for assay and related substances, USP <711> dissolution testing in 0.1 M HCl and pH 6.8 phosphate buffer, USP <905> uniformity of dosage units, and forced-degradation profiling under ICH Q1A and ICH Q1B conditions. Compliance over the granule and tablet process is framed by ICH Q3D, ICH Q3C, ICH M7, and FDA 21 CFR 210/211 for early-phase clinical trial material. The terminal finished product types in this scenario are investigational capsules and coated tablets, not licensed oral dosage forms; granules may serve as an intermediate for capsule filling or sachet packaging in clinical supply. Because the oral route is not a licensed indication for epirubicin hydrochloride in major jurisdictions, any tablet or capsule batch is considered a feasibility or clinical trial material, and release specifications must be justified against the approved investigational medicinal product dossier rather than a default commercial oral monograph.

When a ready-to-dilute epirubicin concentrate replaces lyophilised powder in centralised oncology compounding

When the input stream is a ready-to-dilute 2 mg/mL concentrate rather than a lyophilised cake, centralised oncology compounding must revalidate the high-potency liquid handling path under USP <797> and USP <800>; the removal of reconstitution shortens preparation time but shifts the risk to gravimetric transfer accuracy and closed-system transfer device compatibility. The addition ratio for patient-specific infusion is derived from the prescribed dose and the final concentration tolerance: the 2 mg/mL concentrate is drawn gravimetrically into a closed-system transfer device and diluted with 0.9% sodium chloride or 5% glucose to a final concentration of 0.2–1.0 mg/mL; the final infusion volume is typically 50–250 mL. Each batch is prepared in an ISO Class 5 laminar airflow workbench or compounding aseptic isolator located in an ISO Class 7 buffer room, with pressure differentials continuously monitored to 10–15 Pa positive-to-corridor. Gravimetric verification uses a balance precision of 0.01 g; the final container is a light-protected PVC-free infusion bag or an elastomeric infusor for ambulatory administration. Beyond-use dating is assigned according to USP <797> risk categories; institutional policies frequently assign 24 h at room temperature or 72 h refrigerated for this type of closed-system admixture, with longer storage permitted only where stability data and validated sterility assurance support the assigned window. Compliance evidence includes extractable/leachable evaluation for the elastomeric closure and infusion tubing under USP <381>, particulate monitoring under USP <788>, and data-logging of cold-chain storage at 2–8 °C with excursion alarms. Finished product types are patient-specific intravenous infusion bags, ambulatory elastomeric infusors, and compounded syringe reservoirs for infusion pumps. Operational boundaries include the risk of pH-dependent precipitation in bicarbonate-containing fluids, incompatibility with alkaline solutions, and the need to protect the final admixture from light during the entire infusion period.

Regionally, chemoembolization microsphere loading with epirubicin hydrochloride has been reported in a limited set of hepatic arterial chemoembolization protocols; the loading operation is not covered by the epirubicin hydrochloride API monograph, and release testing is driven by the drug-device combination protocol rather than a pharmacopoeial product specification. The starting material is a sulphonate-modified polyvinyl alcohol hydrogel microsphere with calibrated diameter fractions, typically 100–300 µm, hydrated in water for injection. Epirubicin hydrochloride solution is added to the hydrated bead suspension under continuous gentle agitation; the drug-loading ratio is calculated by HPLC depletion of the supernatant at 254 nm, so the bound amount is expressed as milligrams epirubicin per millilitre of hydrated microspheres. Published feasibility evaluations for anthracycline-loaded drug-eluting beads report added drug concentrations from 5 mg/mL to 25 mg/mL hydrated bead volume, but published data specific to epirubicin hydrochloride across all bead size fractions are limited; the loading endpoint must therefore be confirmed by mass balance for each batch. The downstream process is performed in a hospital interventional radiology or nuclear medicine radiopharmacy or a compounding cleanroom under USP <797> and USP <800> hazardous drug controls, using closed syringes and shielded mixing vials to restrict aerosol and splatter exposure. The finished product type is a single-use loaded microsphere suspension for selective intra-arterial administration through a microcatheter; it is not an injectable solution and must not be diluted further after loading. Compliance includes ICH Q3D elemental impurities for the API starting material, USP <85> bacterial endotoxins for the hydrating water and device components, and sterility assurance appropriate to the route of administration; residual unbound epirubicin in the supernatant is assayed by stability-indicating HPLC. Operational boundaries include bead size-dependent loading capacity, possible ionic-strength interference from saline-containing diluents, and the need to avoid vigorous agitation that damages microsphere integrity; the final suspension should be used immediately after loading because prolonged standing can alter elution kinetics.